Presscuff
Presscuff introduces the world's first pressure-based endotracheal tube to the market. This innovative technology is designed to significantly reduce the incidence of pneumonia in patients receiving intensive care. During artificial ventilation in the ICU, a ventilation tube is typically inserted into the patient's throat to deliver air directly to the lungs. However, the use of such tubes can lead to pneumonia in as many as one in four patients. According to academic studies, 10 to 15% of these patients die as a result of pneumonia. By addressing this critical issue, Presscuff's groundbreaking technology has the potential to save countless lives and improve the quality of care in intensive care units around the world.
The Presscuff tube employs a unique approach to manage secretions in the trachea. Rather than attempting to close the small openings in the trachea, the Presscuff tube utilizes them to obstruct the secretions. Air pressure is introduced between the two cuffs, and it naturally seeks to escape through the channels of the cuffs both upward and downward. By directing the air pressure upwards, the Presscuff tube effectively prevents secretions from flowing downward.
The spin-off was founded by Emiel Suijs, former head nurse of the Intensive Care Unit at UZ Brussel, and VUB Prof Dr Spapen, former head of the Intensive Care Unit.
